Company Overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

  • Name

    Royalty Pharma plc

  • CEO

    Mr. Pablo Gerardo Legorreta

  • Website

    www.royaltypharma.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1996

Profile

  • Market Cap

    $12.42B

  • EV

    $21.5B

  • Shares Out

    448.13M

  • Revenue

    $2,237.63M

  • Employees

Margins

  • Gross

    55.46%

  • EBITDA

    63.61%

  • Operating

    42.91%

  • Pre-Tax

    46.02%

  • Net

    30.09%

  • FCF

    119.28%

Returns (5Yr Avg)

  • ROA

    4.6%

  • ROTA

    8.05%

  • ROE

    8.03%

  • ROCE

    8.72%

  • ROIC

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $44.75

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $1,803.14M

  • Net Debt

    $5,798.88M

  • Debt/Equity

    0.78

  • EBIT/Interest

    5.15

Growth (CAGR)

  • Rev 3Yr

    -0.01%

  • Rev 5Yr

    5.58%

  • Rev 10Yr

  • Dil EPS 3Yr

    -15.33%

  • Dil EPS 5Yr

    -41.67%

  • Dil EPS 10Yr

  • Rev Fwd 2Yr

    9.8%

  • EBITDA Fwd 2Yr

    -0.37%

  • EPS Fwd 2Yr

    0.09%

  • EPS LT Growth Est

    4.2%

Dividends

  • Yield

  • Payout

    54.63%

  • DPS

    $0.82

  • DPS Growth 3Yr

    8.61%

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

    10.01%

NasdaqGS:RPRX